Science & Insights / Body composition

Retatrutide vs Tesamorelin

Weight loss, visceral fat and the limits of “stacking”.

By Everform Pharma
Updated 18 November 2026

Ivory weighing scales, an emerald measuring tape and a green notebook on travertine in warm natural light.
Conceptual AI-generated image illustrating weight and body-composition research.

Retatrutide and tesamorelin are often presented as a simple partnership: one reduces body weight, while the other targets deep abdominal fat and protects muscle. That explanation is memorable, but it goes further than the evidence allows.

Both compounds have been studied for changes in fat distribution, through different biological pathways and in different populations. Evidence for either compound alone does not establish that combining them produces a better result.

At Everform Pharma in Da Nang, Vietnam, our educational approach starts with three questions: what was measured, who was studied, and what remains unproven?

The scale measures weight—not where it comes from

Body weight includes fat, muscle, water, bone and other tissues. A change in weight does not identify which of those changed.

Fat distribution matters too. Subcutaneous fat sits beneath the skin; visceral fat lies within the abdomen around internal organs. Liver fat is another distinct measurement. A smaller waist does not precisely quantify any one of these compartments.

This is why studies of body composition use measurements such as CT, MRI or DXA rather than relying solely on scales or photographs. The retatrutide imaging substudy, for example, assessed liver and abdominal fat directly. [3]

Retatrutide: three receptors, broad metabolic research

Retatrutide activates the GIP, GLP-1 and glucagon receptors. Its clinical research has examined body weight, metabolic outcomes and fat distribution. It is inaccurate to reduce its action to appetite suppression alone—or to describe its glucagon activity as a simple switch that makes the liver “burn off” fat. [1][2][3]

In the 2023 phase 2 obesity trial, the highest study group had an average weight reduction of 24.2% at 48 weeks, compared with 2.1% with placebo. More recent phase 3 results published in 2026 reported an average reduction of 25.0% in the highest study group at 80 weeks, versus 3.9% with placebo. These are group averages from separate studies, not individual predictions or a direct comparison between trial programmes. [1][2]

An imaging substudy also reported reductions in liver fat, visceral abdominal fat and abdominal subcutaneous fat. Retatrutide therefore does not leave visceral fat exclusively to another compound. [3]

As of November 2026, Lilly describes retatrutide as investigational and not approved by a regulatory authority. Published trial results do not make a separately supplied research product an approved medicine. [8]

Tesamorelin: a different pathway and a specific clinical context

Tesamorelin is a growth hormone-releasing hormone analogue. It stimulates pituitary growth hormone secretion and raises IGF-1. This differs from retatrutide’s receptor profile, but a different mechanism does not automatically mean an additive benefit. [4][7]

Its strongest established clinical context is excess abdominal fat in adults with HIV-associated lipodystrophy. In a pivotal 26-week trial involving 412 participants with HIV and abdominal fat accumulation, visceral fat decreased by 15.2% with tesamorelin and increased by 5.0% with placebo. [4]

The US prescribing information for EGRIFTA WR specifically states that it is not indicated for weight-loss management. Describing tesamorelin as a general weight-loss medicine would therefore misrepresent its labelled use. [7]

Research outside HIV also exists. A randomised study of 60 adults with abdominal obesity and reduced growth hormone secretion reported a reduction in visceral fat, without a significant effect on abdominal subcutaneous fat. That selected population should not be treated as representative of every healthy adult seeking a smaller waist. [5]

A separate trial in people with HIV and abdominal fat accumulation reported reductions in both visceral and liver fat. Again, the findings belong to that study population and formulation. [6]

Lean mass is not the same as muscle growth

A common leap in online discussions is treating an increase in lean mass as proof that tesamorelin builds muscle or prevents muscle loss during retatrutide-associated weight reduction.

Lean mass includes water and tissues other than skeletal muscle. Changes in fluid balance can affect the measurement; tesamorelin’s prescribing information includes fluid retention among its warnings. [7]

Consequently, an increase in measured lean mass should not automatically be described as stronger muscles, better physical function or protection against muscle loss during treatment with another compound. Those questions require direct measurements and appropriately designed studies.

Comparing the evidence fairly

QuestionRetatrutideTesamorelin
Main pathwayGIP, GLP-1 and glucagon receptor agonismStimulation of the growth hormone–IGF-1 axis
Important study populationsAdults with obesity; selected metabolic-disease populationsPrimarily adults with HIV-associated abdominal fat accumulation; some selected non-HIV populations
Visceral-fat findingsReductions reported in imaging researchReductions reported in randomised trials
General weight-loss roleInvestigational obesity-treatment programmeEGRIFTA WR is not indicated for weight-loss management
Proven muscle protection when pairedNot established by the cited studiesNot established by the cited studies
Evidence that the combination is superiorThe cited trials did not test the pairThe cited trials did not test the pair

This is a comparison of research contexts, not a head-to-head efficacy ranking.

Does combining them make scientific sense?

There is a rationale for asking whether different pathways might produce complementary effects. That is a research question—not confirmation of compatibility, safety or superiority.

The studies cited here do not test retatrutide and tesamorelin together. They cannot establish an optimal combination, identify who benefits from adding one to the other, or demonstrate that tesamorelin offsets lean-tissue changes during retatrutide-associated weight loss.

Nor can one compound be assumed to cancel another’s risks. Tesamorelin’s label warns about elevated IGF-1, glucose intolerance or diabetes, and fluid retention, and lists active malignancy among its contraindications. Retatrutide’s phase 2 trial reported gastrointestinal adverse events and dose-dependent increases in heart rate. [1][7]

An “ultimate recomposition stack” is therefore a marketing description, not a conclusion supported by these trials.

Can waist and strength changes reveal which compound is working?

Weight trends, waist measurements and strength records can describe progress. They cannot reliably attribute a change to one compound when several interventions change together.

A stable scale alongside a smaller waist could reflect changes in fat, water, muscle, gut contents or measurement technique. It is not a specific signature of tesamorelin activity. Likewise, maintaining strength does not prove that no muscle was lost.

Imaging can provide more specific body-composition information, but even a scan does not establish which compound caused a change without a suitable comparison. Attribution requires a study design—not simply a more convincing-looking progress photograph.

Reading peptide research with Everform

The useful distinction is not “retatrutide for weight, tesamorelin for the belly”. Both have research involving visceral fat, but their mechanisms, studied populations, endpoints and regulatory contexts differ.

When reviewing a claim, check whether it concerns an individual compound or a combination, whether the measurement was body weight or a specific tissue compartment, and whether the formulation and population match the claim being made.

Understanding those boundaries makes the science more useful—and prevents promising findings from becoming promises the evidence cannot support.


Everform Pharma · Da Nang, Vietnam Educational information. Not medical advice. Research products are for laboratory research only. Not for human or veterinary use.

References

1. Jastreboff et al. Retatrutide phase 2 obesity trial. New England Journal of Medicine, 2023. ↗

2. Jastreboff et al. Retatrutide phase 3 obesity trial, TRIUMPH-1. New England Journal of Medicine, 2026. ↗

3. Retatrutide randomised phase 2a MASLD imaging substudy. Nature Medicine, 2024. ↗

4. Falutz et al. Tesamorelin trial in patients with HIV and abdominal fat accumulation. New England Journal of Medicine, 2007. ↗

5. Makimura et al. Tesamorelin in adults with abdominal obesity and reduced growth hormone secretion. Journal of Clinical Endocrinology & Metabolism, 2012. ↗

6. Stanley et al. Tesamorelin and visceral and liver fat in patients with HIV. JAMA, 2014. ↗

7. EGRIFTA WR US prescribing information. ↗

8. Eli Lilly. Retatrutide development and regulatory-status information, updated October 2026. ↗

© 2026 Everform Pharma · Da Nang, Vietnam · Scientific educationBack to top ↑